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Abstract
Background: The control and elimination of malaria requires expanded coverage of and access to effective malaria
control interventions such as insecticide-treated nets (ITNs), indoor residual spraying (IRS), intermittent preventive
treatment (IPT), diagnostic testing and appropriate treatment. Decisions on how to scale up the coverage of these
interventions need to be based on evidence of programme effectiveness, equity and cost-effectiveness.
Methods: A systematic review of the published literature on the costs and cost-effectiveness of malaria
interventions was undertaken. All costs and cost-effectiveness ratios were inflated to 2009 USD to allow
comparison of the costs and benefits of several different interventions through various delivery channels, across
different geographical regions and from varying costing perspectives.
Results: Fifty-five studies of the costs and forty three studies of the cost-effectiveness of malaria interventions were
identified, 78% of which were undertaken in sub-Saharan Africa, 18% in Asia and 4% in South America. The median
financial cost of protecting one person for one year was $2.20 (range $0.88-$9.54) for ITNs, $6.70 (range $2.22-
$12.85) for IRS, $0.60 (range $0.48-$1.08) for IPT in infants, $4.03 (range $1.25-$11.80) for IPT in children, and $2.06
(range $0.47-$3.36) for IPT in pregnant women. The median financial cost of diagnosing a case of malaria was
$4.32 (range $0.34-$9.34). The median financial cost of treating an episode of uncomplicated malaria was $5.84
(range $2.36-$23.65) and the median financial cost of treating an episode of severe malaria was $30.26 (range
$15.64-$137.87). Economies of scale were observed in the implementation of ITNs, IRS and IPT, with lower unit
costs reported in studies with larger numbers of beneficiaries. From a provider perspective, the median incremental
cost effectiveness ratio per disability adjusted life year averted was $27 (range $8.15-$110) for ITNs, $143 (range
$135-$150) for IRS, and $24 (range $1.08-$44.24) for IPT.
Conclusions: A transparent evidence base on the costs and cost-effectiveness of malaria control interventions is
provided to inform rational resource allocation by donors and domestic health budgets and the selection of
optimal packages of interventions by malaria control programmes.
Background
Despite being a largely preventable and treatable disease,
malaria is responsible for an estimated 800,000 deaths
globally each year [1], with the majority of morbidity
and mortality occurring in young children in sub-
Saharan Africa. In addition to its impact on health,
malaria imposes a heavy economic burden on indivi-
duals [2] and entire economies [3]. In response to calls
for widespread control and elimination of malaria and
the challenge of meeting the Millennium Development
Goals, there has been a rapid scale-up of existing effec-
tive anti-malaria interventions, in particular insecticide-
treated mosquito nets (ITNs) including long-lasting
insecticidal nets (LLINs) [4-7], coupled with efforts to
improve access to prompt and effective treatment [8,9].
There is a wide range of malaria control interventions
whose efficacy and effectiveness have been repeatedly
demonstrated over many years, including ITNs [10] and
indoor residual spraying (IRS) [11], and interventions
that have recently received increasing attention such as
the use of artemisinin combination therapy (ACT) as
first-line therapy [12], improved diagnosis using rapid
diagnostic tests (RDTs) [13,14], and intermittent
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any medium, provided the original work is properly cited.preventive treatment (IPT) [15-17]. In this review IPT is
used as an umbrella term for intermittent preventive
treatment in infants (IPTi), in children (IPTc), and in
pregnant women (IPTp).
Having identified a range of interventions with proven
efficacy, the challenge remains to scale-up their imple-
mentation in a sustainable, cost-effective and equitable
manner. Decisions affecting the selection and coverage
of interventions need to be taken in a rational, transpar-
ent manner using the best available evidence on efficacy,
cost and cost-effectiveness. There have been a number
of reviews looking at the efficacy and effectiveness of
malaria interventions [10-12] and reviews of the costs
and cost-effectiveness (CE) of selected interventions
[18-20]. The seminal work of Goodman et al [21]
reviewed and modelled the CE of a range of malaria
interventions. Morel et al [22] made another significant
contribution to the literature by using a model based on
WHO CHOICE country estimates of general health care
utilization costs [23] to estimate the cost-effectiveness of
packages of malaria prevention and treatment interven-
tions. However, there has not been a review of actual
costs and CE of malaria treatment and prevention pro-
grammes in the last decade, despite the fact that these
are likely to have changed with increasing economies of
s c a l e( t h ed e c r e a s ei nu n i tc ost per intervention as the
number of interventions delivered increases), and evol-
ving market dynamics of the relatively new LLINs, ACT
and RDTs. The need for such a review is timely given
the changing global financial commitment to malaria
[1,24] and the need for country-level decision making
on which of the increasing number of tools have the
greatest impact on reducing malaria with the minimum
cost and are therefore the most efficient use of
resources.
A systematic review of the published literature on the
cost and cost-effectiveness of malaria control interven-
tions published from 2000-2010 is presented. Studies
published in this time period were implemented from
1990-2010. Unlike other reviews, which are generally
country-specific [25] or focus on a single intervention
strategy [18,26], the costs and CE of interventions over
time and across world regions are presented and com-
pared. All data is synthesized to allow cross-comparison
between different interventions and study locations, and
the full details extracted from each identified study are
made available as Supplementary Online Material.
Methods
Review of cost and cost-effectiveness studies
A systematic search of the published English-language
literature on studies of the cost of all malaria interven-
tions published between 2000 and 2010 was conducted
using the electronic online database PubMed. These
studies were implemented between 1990 and 2010. The
MESH term used was ‘(malaria OR falciparum) AND
cost’. This was supplemented by searches of Google
Scholar and African Journals Online using the same
MESH term as well as iterative reviews of the reference
lists of relevant published papers and searches of the
grey literature consisting of PhD theses and reports
identified in references, reports to WHO from consulta-
tion projects for the evaluation of the costs of ITN dis-
tribution and additional searches on the Social Science
Research Network and the Bath Information Data Sys-
tem. In addition, searches for costing studies of Plasmo-
dium vivax, Plasmodium ovale and Plasmodium
malariae were undertaken. All the abstracts from the
identified publications were reviewed and the publica-
tions selected for review if they contained primary data
on the cost of one or more malaria interventions.
A proportion of the studies identified in the review of
the costs of malaria interventions contained estimates of
cost-effectiveness. These studies were supplemented by
an additional systematic search of the cost-effectiveness
literature to identify those studies providing cost-effec-
tiveness estimates but not primary cost estimates. The
MESH terms used were: ‘(malaria OR falciparum) AND
(cost OR effective OR effectiveness OR benefit)’. As only
thirty three published studies of cost-effectiveness were
identified in the period 2000-2010, the search was
extended to consider studies published in the period
1990-2010. These searches were further supplemented
by iterative reviews of the reference lists of relevant pub-
lished papers and searches of the grey literature consist-
ing of PhD theses and reports. Abstracts and full
publications were reviewed a n di n c l u d e di ft h e yc o n -
tained estimates of the cost-effectiveness of interven-
tions in terms of health outcomes.
The selected studies were stratified into six categories
according to intervention: ITNs, IRS, IPT, diagnostics,
treatment and other. For each study the information in
Figure 1 was extracted where available. Where possible,
both the financial and economic costs were extracted.
Where an ingredients approach to costing was used, the
cost was split into the following categories: ‘nets’, ‘insec-
ticide’, ‘diagnostics’, ‘treatment’, ‘personnel’, ‘training’,
‘IEC’, ‘distribution’, ‘transport’, ‘storage’, ‘overheads’,
‘capital’, ‘study costs’, ‘other’ and ‘user’.W h e r es t u d i e s
reported the costs for multiple outcomes, e.g. cost per
ITN distributed or cost per person protected with ITNs,
the cost for each outcome was extracted.
Where reported, the results of sensitivity analyses
were extracted from the studies. In some studies the
sensitivity analyses are 95% confidence intervals when
intervention parameters and costs are varied simulta-
neously according to some distribution. However, most
studies, and in particular those published before the
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include a simple one-way sensitivity analysis where one
parameter at a time is varied. In these studies the limits
of the sensitivity analyses were taken to be the highest
and lowest estimates of costs or cost-effectiveness ratios.
All of the extracted information can be found in Addi-
tional File 1 ‘CostReview.xls’.
Costs
Financial and economic total costs are presented if both
were identified in the original paper. Financial costs
reflect the unit cost of an intervention and the resources
required for its delivery in terms of the actual expendi-
tures incurred. The economic costs capture the oppor-
tunity cost of all resources used to provide an
intervention, whether or not they incur a financial
expenditure. For example, the time health personnel are
involved in treating malaria often represents an eco-
nomic cost, because they are already receiving a salary
for the broad range of services they provide and, while
they do not receive additional funding for the specific
malaria intervention being assessed, they could have
spent their time on other activities. Alternatively, if
drugs have been donated or community volunteers are
helping for ‘free’, an economic cost will attach a market
value to these resources. Although economic costs pro-
vide a better of measure of the total costs associated
with distributing interventions, a much larger propor-
tion of interventions reported financial costs, and hence
financial costs are focussed on in this review. Costs are
commonly collected from two different perspectives:
provider and societal. The first relates to the costs,
usually borne by the public health system, of providing
preventive or treatment strategies. The second perspec-
tive, societal, refers to the wider direct and indirect
costs not only to the provider but also to the household
in terms of their lost time and income.
Once delivered, preventive interventions such as ITNs,
IRS and IPT will provide protection against malaria for
a number of months or years. The duration of protec-
tion offered by an intervention will have cost implica-
tions as it will determine when the intervention next
needs to be delivered. For example, if IRS provides pro-
tection for six months, then spraying will be required
twice yearly to provide constant protection. To allow
greater comparability between interventions the standar-
dized annual costs of protecting one person for a full
year with ITNs, IRS or IPT was calculated. Standardiza-
tion was not undertaken for diagnosis and treatment
since the annual cost of these interventions depends on
local incidence of malaria.
The cost per treated net year (TNY) captures the cost
of ensuring one person is protected by an appropriately
treated bed net for one year. The standardized cost of
protection with ITNs was taken to be the cost per TNY
for those studies reporting TNYs. Where TNYs were
not reported, the standardized cost was taken to be the
financial cost divided by the lifetime of the ITN. When
the lifetime of the ITN was not reported, a three-year
lifetime was assumed. Financial, and not economic,
costs are more often discussed in light of the greater
number of studies that presented their findings as finan-
cial costs. Some costing studies of IRS provided esti-
mates of the cost of protection per person per year,
while some provided estimates of the cost of a spray
round per person. Where the cost of protection per per-
son per year was not estimated, a standardized financial
cost of protection per year was calculated by assuming
two spray rounds were necessary for a full year of pro-
tection. This method does not account for the seasonal
nature of malaria transmission and the additional benefit
obtained by spraying before the rainy season. The stan-
dardized cost of a year’s protection with IPT was calcu-
lated by extrapolating to the number of courses
required for a year’s protection. In the case of IPTp, it is
assumed that there is only one pregnancy per year, and
hence the cost of a year’s protection is equal to that of
protection throughout pregnancy. In the case of seaso-
nal administration of IPT to school-age children, it was
assumed that protection during the rainy season pro-
vided protection throughout the year and hence the
standardized annual cost was assumed equal to the unit
financial cost.
When reporting the cost of an intervention from a
number of studies the median and range is given instead
of the mean as this prevents the summary measure of
Figure 1 Information extracted from cost studies.
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costing were carried out, data from the most recent year
was taken.
Inflation of costs
The costs of the interventions surveyed in this review
were extracted from studies evaluating costs in a range
of international currencies over a period of time dating
back to 1990. In order for meaningful comparisons
between costs from different studies to be made, costs
were adjusted to a common year and a single currency.
Costs of interventions are first converted from local cur-
rency to US dollars using the exchange rate at the year
of costing and then inflated to 2009 USD using USD
inflation rates. There are alternative methods for inflat-
ing the costs of interventions [27], see Appendix 1 for
more details.
Throughout, the years reported in the results section
refer to the year the costs were collected and not the
year they were published.
Effects
Only studies reporting cost-effectiveness ratios against
endpoints relevant to health-related malaria outcomes
were included in the comparison of cost-effectiveness
outcomes. Thus, studies calculating incremental cost-
effectiveness ratios (ICERs) per DALY averted, malaria-
associated deaths averted or malaria cases averted were
included. Studies calculating intermediate outcomes,
such as ICERs per ITN distributed or house sprayed
were excluded as these did not directly relate to a health
outcome, making generalization and comparison with
other studies more difficult. There was substantial varia-
tion in the definition of a case of malaria between stu-
dies, ranging from parasitaemia to clinical or severe
episodes of malaria, to inclusion of co-morbidities such
as anaemia. The definition of a case of malaria will sig-
nificantly influence the reported cost-effectiveness. For
example, if the incidence of uncomplicated clinical
malaria is higher than the incidence of severe malaria
then it will be cheaper to avert an uncomplicated case
than a case of severe malaria. There are substantial pro-
blems associated with accurately determining the num-
ber of cases of malaria or deaths averted by an
intervention. The impact on CE of variation in the num-
ber of reported cases of malaria will be partially
addressed by sensitivity analyses, at least in those studies
where they are carried out. Cost-effectiveness studies do
not all have the same ‘starting point’.I ti si m p o r t a n tt o
note when interpreting the effects of an intervention
that the baseline packages of interventions already avail-
able can vary considerably across studies and this is not
always made explicit. For example, the cost effectiveness
of an intervention is likely to appear much more
favourable in a setting where very few other malaria
strategies are in place, whereas the impact of the same
intervention is likely to have a less marked effect, and
hence appear less cost effective, in a setting where ITN
coverage is high and widespread, prompt and effective
treatment is on offer. In addition cost effectiveness will
depend on the intensity of malaria transmission and the
behavioural characteristics of the local vector
population.
Results
Costs of malaria interventions
In total, fifty five relevant costing studies were identified,
thirty three of which also included estimates of cost-
effectiveness. An additional ten studies reporting cost-
effectiveness estimates but no primary cost data were
identified resulting in a total of forty three relevant cost-
effectiveness studies (Figure 2). The interventions stu-
died included ITNs, IRS, IPTi/c/p, vaccines, malaria
diagnostics, treatment of uncomplicated malaria, treat-
ment of severe malaria in health centres or hospitals,
larviciding, larvivorous fish, malaria early warning sys-
tems, environmental management, drug treatment, rapid
diagnostics, and combined prevention and treatment
programmes. There was a great deal of heterogeneity in
the type of costing study identified: randomized con-
trolled trials of intervention efficacy including detailed
costing information; large scale intervention pro-
grammes implemented on a regional or national level,
involving estimates of costs extrapolated from data col-
lected from health officials; and model-based studies
combining data from different sources to produce esti-
mates of cost. Overall the studies were identified from
countries throughout malaria endemic areas of the
world, but with a heavy focus on Sub-Saharan Africa
(78% of studies). Within Africa, most were conducted in
East Africa, in particular Kenya and Tanzania, and The
Gambia in West Africa. A geographical comparison of
study locations and the burden of P. falciparum malaria
[ 2 8 ]i ss h o w ni nF i g u r e3 .T h e r ea r em a n yc o u n t r i e s
with a high burden of malaria but little or no studies of
the cost or cost-effectiveness of malaria interventions. A
large proportion of the studies were undertaken between
2005-2010, many of these relating to new interventions,
in particular IPTi/c/p (Figure 4).
Insecticide-treated nets
Twenty-two studies of the costs of distributing ITNs
were identified, ten of which were for the distribution of
LLINs (Additional file 2: Table S1). The studies mea-
sured the cost of a number of different outcomes: (i)
cost per net distributed; (ii) cost of distribution only
(excluding the cost of net purchase); (iii) cost per trea-
ted net year (TNY), i.e. year of effective protection; and
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a number of ways. There is variation in how studies
include insecticide re-treatment. In some studies, con-
ventional ITNs were distributed pre-treated with insecti-
cide, in others ITNs are distributed with sachets of
insecticide for treatment by the users, and other studies
include the cost of re-treatment some time after distri-
bution. The cost per TNY captures the added costs and
benefits associated with insecticide re-treatment,
although most studies preferred to present cost per net
distributed. The recent shift to distribution of LLINs
instead of conventional ITNs has made comparison of
costs easier as the additional costs associated with insec-
ticide re-treatment are avoided.
The cost per ITN distributed is typically higher than
the cost per person protected by a net, as it is usually
Figure 3 Geographical location of costing and cost-effectiveness studies. A: Map of P. falciparum parasite prevalence in Africa estimated in
2007 from the Malaria Atlas Project [27]. B: Geographical location of African based studies of cost and cost-effectiveness. 78% of reviewed
studies were located in Africa, 18% in Asia and 4% in South America.
Figure 2 Search strategy for costing studies. The number of cost and cost-effectiveness studies identified in each category is shown (left-
hand number is cost/right-hand number is cost-effectiveness (CE)).
White et al. Malaria Journal 2011, 10:337
http://www.malariajournal.com/content/10/1/337
Page 5 of 14assumed that nets are shared (e.g. mother and child).
However some studies estimate the cost of delivering an
ITN to a target group, such as newborn infants, in
which case the cost per person protected in the target
group may be more than the cost per ITN delivered (e.
g. to ensure infants are covered by nets more than one
net may need to be distributed per infant, as some nets
may be used by other family members.).
The median financial cost per ITN distributed (in the
first year) was $7.03 ranging from $2.97-$19.20 whilst
the median economic cost (across the expected lifetime
of the net) was $4.15 ranging from $2.97-$10.05. The
median standardized financial cost for a year’sp r o t e c -
tion with ITNs was $2.20 ranging from $0.88-$9.54.
Across the studies that reported a detailed breakdown
of costs, a mean proportion of 63% (range 12%-92%) of
the cost of distributing a net was attributable to nets
and insecticide, 17% (range 2%-67%) was attributable to
personnel and training, and 7% (range 1%-17%) to IEC
and transport (Figure 5).
Indoor residual spraying
Seven studies of the costs of spraying houses with
indoor residual insecticide were identified (Additional
file 3: Table S2). Two different outcomes were measured
across the studies: (i) cost per person protected, and (ii)
cost per dwelling sprayed. All studies estimated the cost
per person protected and four studies estimated the cost
per dwelling sprayed. There was much variation in the
seven studies identified with locations from Africa, Asia
and South America, different insecticide classes and dif-
ferent periods of protection. The IRS studies were all
relatively old - the most recent year of costing was 2001
(Figure 4). The number of spray rounds and the
timeframe of protection varied between studies, as such
reported financial and economic costs cannot be directly
compared between studies. Direct comparisons can be
made between standardized financial costs which have
been adjusted to have a timeframe for protection of one
year. The median financial cost per person protected by
IRS was $3.91 ranging from $1.11-$12.87 whilst the
median economic cost was $3.41 ranging from $1.14-
$6.23. The median standardized cost of a year’s protec-
tion with IRS was $6.70 ranging from $2.22-$12.85. The
relationship between cost per person protected and cost
per house sprayed varied depending on the number of
people per house, which varied from 1.6 to 5.4. Several
different insecticide formulations were used in the stu-
dies: DDT and the pyrethroids, deltamethrin and lamb-
dacyhalothrin. The mean proportion of the cost
attributable to the cost of insecticide was 49% (range
29%-81%), and the mean proportion attributable to per-
sonnel and training was 34% (range 4%-48%) (Figure 5).
Intermittent preventive treatment
Eight studies of the costs of administering a course of
intermittent preventive treatment were identified: two of
these studies were for IPT in infants (IPTi), three for
IPT in children (IPTc), and three for IPT in pregnant
women (IPTp) (Additional file 4: Table S3). The median
financial cost of protection was $0.10 (range $0.08-
$0.18) for IPT in infants, $4.03 (range $1.25-$11.80) for
IPT in children, and $2.06 (range $0.47-$3.36) for IPT
in pregnant women. Full treatment with IPTp is
assumed to confer protection for a timeframe of one
year (assuming no more than one pregnancy per year);
full treatment with IPTc is assumed to confer protection
for a timeframe of one year; and a dose of IPTi is
Figure 4 Year of costing of cost and cost-effectiveness studies. The year refers to when the intervention was costed and not the
publication year.
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Page 6 of 14Figure 5 Unit financial costs of malaria control interventions broken down into components. A: Unit financial cost per ITN distributed.
Data is taken from Additional file 2: Table S1. B: Unit financial cost per person protected by IRS. Data is taken from Additional file 3: Table S2. C:
Unit financial cost per course of IPT. (i) indicates IPT in infants, (c) IPT in children, and (p) IPT in pregnant women. Data is taken from Additional
file 4: Table S3. D: Financial cost of diagnosing a patient for malaria. Data is taken from Additional file 5: Table S4. E: Financial cost of diagnosis
and treatment with ACT. Data is taken from Additional file 5: Table S4. F: Financial cost of treatment of either uncomplicated or severe malaria.
(u) indicates uncomplicated malaria and (s) severe malaria. Data is taken from Additional file 6: Table S5. All studies were costed from a provider
perspective except those marked * which were costed from a societal perspective. All costs are in 2009 USD.
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dies reported the costs of administering IPT with vary-
ing number of courses and doses, the standardized cost
of a year’s protection was also calculated. The median
cost of a year’s protection was $0.60 (range $0.48-$1.08)
for IPTi, $4.03 (range $1.25-$11.80) for IPTc, and $2.06
(range $0.47-$3.36) for IPTp. Personnel and training
accounted for the majority of the costs of administering
a course of IPTi and IPTp, as the drug used (sulphadox-
ine pyrimethamine) was relatively inexpensive. The
median cost of administering IPT to infants and preg-
nant women was substantially less expensive than the
costs of administration to children as the drugs can be
delivered to infants alongside vaccinations in the well-
established Expanded Programme on Immunization and
to pregnant women through existing ANC clinics. For
IPTi on average 48% (range 14%-71%) of the cost of a
course of treatment was attributable to the cost of
drugs, 37% (range 24%-56%) to personnel and training,
and 15% (range 5%-40%) to transport and IEC. For IPTc
on average 13% (range 8%-60%) of the cost of a course
of treatment was attributable to the cost of drugs, 60%
(range 47%-77%) to personnel and training, and 25%
(range 13%-49%) to transport and IEC. For IPTp on
average 22% (range 9%-39%) of the cost of a course of
treatment was attributable to the cost of drugs, 67%
(range 45%-79%) to personnel and training, and 11%
(range 0%-42%) to transport and IEC (Figure 5).
Diagnosis and treatment
Nine studies of the costs of malaria diagnosis were iden-
tified (Additional file 5: Table S4). The diagnostic tools
used were clinical observation of symptoms, detection of
parasites by microscopy or rapid diagnostic tests
(RDTs). The studies measured combinations of the fol-
lowing outcomes: (i) cost per patient diagnosed (seven
studies); and (ii) cost per patient diagnosed and treated
(six studies). The financial costs per patient diagnosed,
and per patient diagnosed and treated are shown in
Additional file 5: Table S4. All studies comparing the
cost of P. falciparum diagnosis (but not the cost of
treatment) by RDTs and microscopy found RDTs to be
more cost-effective. A Sri Lankan study [29] comparing
the cost of P. vivax by RDT and microscopy found
microscopy to be most cost-effective, a finding attributa-
ble to the high cost of the immunochromatographic test
for P. vivax. There were two studies comparing the
costs of diagnosis and treatment with RDTs and micro-
scopy: one study found RDTs to be less expensive [30]
while the other found microscopy to be more cost-effec-
tive [31]. Two studies compared the cost of RDT diag-
nosis and ACT treatment with presumptive ACT
treatment; one found RDT diagnosis to be more cost-
effective [32], whereas the other found presumptive
treatment to be more cost-effective [33]. These appar-
ently conflicting results are due to differences in where
diagnosis occurs and diagnostic throughput, and hence
may not be generalise to other settings. Diagnosis by
microscopy will be inexpensive in a well-established
health centre or hospital with trained microscopists,
whereas RDTs will be less expensive in more inaccessi-
ble rural areas. The cost of diagnosis and treatment will
also be dependent on parasite prevalence. On average
39% (range 13%-99%) of the cost of diagnosing a case of
malaria was attributable to the diagnostic technique and
42% (range 1%-83%) to personnel and training. For stu-
dies of diagnosis and treatment, 27% (range 12%-95%)
of the cost was attributable to diagnosis, 41% (range 5%-
47%) to treatment, and 17% (range 0%-56%) to person-
nel and training (Figure 5).
Treatment of uncomplicated and severe malaria
Patients with episodes of uncomplicated malaria can be
treated at home by community health workers, at health
facilities or as hospital outpatients. In addition to those
studies on diagnosing and treating uncomplicated
malaria identified in the section on diagnosis, five stu-
dies of the costs of treating uncomplicated episodes of
malaria were identified (Additional file 6: Table S5).
Three studies estimated the cost of hospital treatment
from the provider’s perspective and two studies esti-
mated the cost from a societal perspective. All studies
estimated either the financial or economic cost of treat-
ing an episode of malaria with a number of drugs
including artemisinin combination therapy, sulphadox-
ine-pyrimethamine, chloroquine and quinine. The med-
ian financial cost of treating an episode of
uncomplicated malaria (either as hospital outpatients or
at health centres) was $5.84 (range $2.36-$23.65), and
the median economic cost was $22.48 (range $9.14-
$37.99).
Patients with severe episodes of malaria usually need
to be treated as hospital inpatients to ensure effective
treatment. Six studies of the cost of treating severe epi-
sodes using different treatment regimens of malaria
requiring hospitalization were identified (Additional file
6: Table S5). All studies estimated the cost of hospital
treatment from the provider’s perspective and one study
also estimated the cost from a societal perspective.
There was substantial variation between the cost per
patient treated due to differences in study location, type
of health facility, disease severity, and treatment regime.
The median financial cost of treating a hospital inpatient
was $30.26 (range $15.64-$137.87) and the economic
cost was $64.50 (range $26.99-$288.79).
For patients with uncomplicated malaria, the mean
proportion of costs attributable to personnel and train-
ing was 29% (range 10%-78%), 11% (range 1%-80%) to
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heads and 31% (range 0%-75%) was borne by the
patient. For patients with severe malaria the mean pro-
portion of financial costs attributable to hospital over-
heads was 47% (range 19%-79%), 35% (range 4%-71%) to
personnel and training, and 17% (range 2%-36%) to
treatment and diagnostics.
Effect of scale of study on estimates of cost
There was great variation in the scale of the intervention
programmes and projects analysed in the studies
reviewed: some evaluated the cost of implementing an
intervention based on less than 100 beneficiaries or
patients, while other studies estimated the cost of imple-
menting an intervention to more than 100,000 benefici-
aries. Economies of scale may result in cost savings per
unit when an intervention is widely implemented. Figure
6 shows the relation between cost per beneficiary and
scale of the studies of malaria control interventions (as
measured by the number of beneficiaries). For ITN dis-
tribution (green), there is a trend towards lower distri-
bution costs for larger numbers of beneficiaries, but this
trend is not statistically significant (linear regression P
value = 0.29). In addition there is much less variation in
studies with a larger number of beneficiaries. There is a
trend for lower costs of implementing IRS in studies
with a larger number of beneficiaries (blue), although
this is not significant (linear regression P value = 0.68).
For IPT (red), the cost per course administered
decreases as the number of beneficiaries is increased,
but again this is not statistically significant (linear
regression P value = 0.48).
Cost-effectiveness of malaria interventions
In total, forty eight studies were identified that consid-
ered the cost-effectiveness of malaria interventions
including ITNs, IRS, IPT, vaccines, environmental
management, drug treatment, diagnostics and combined
treatment and prevention. The full results are presented
in Additional file 7: Table S6. The majority of studies
used a provider perspective, with a small number
including a societal perspective. Figure 7 shows the dis-
tribution of the published estimates of the incremental
cost-effectiveness ratios (ICERs) of four interventions
against three different endpoints: cost per case of
malaria averted, cost per death averted and cost per
DALY averted.
From a provider perspective, the median incremental
cost effectiveness ratio per DALY averted was $27
(range $8.15-$110) for ITNs, $143 (range $135-$150) for
IRS, and $24 (range $1.08-$44.24) for IPT. Despite large
variation in delivery costs between studies and settings,
all of the major preventive interventions (ITNs, IRS, and
IPT for infants, children or pregnant women) and ACT
treatment were consistently cost-effective against a
threshold of $150 per DALY averted ($260 at 2009
p r i c e s )[ 3 4 , 3 5 ] .I P T ia n dI P T pw e r ef o u n dt ob et h e
most cost-effective preventive interventions against all
endpoints considered. The superior cost-effectiveness of
IPT was limited to the target groups of infants and
pregnant women, with the CE of IPT in children being
comparable with the CE of ITNs and IRS. Based on the
evidence of this review, it was not possible to determine
conclusively whether ITNs or IRS were more cost-effec-
tive. However, the results of studies comparing both
interventions at the same site by Bhatia et al [36],
Kamolratanakul et al [37] and Goodman et al [38] indi-
cate that ITNs are more cost-effectiveness than IRS, in
contrast to the finding by Guyatt et al [39] that IRS was
more cost-effective than ITNs in response to epidemic
malaria. All studies identified found effective treatment
of episodes of uncomplicated or severe malaria with
ACT to be highly cost-effective when compared to other
anti-malarial drugs.
Figure 6 Economies of scale for ITNs, IRS and IPT. Financial costs per beneficiary of malaria control interventions, as a function of the
number of beneficiaries of the program or project evaluated. Dotted lines represent straight lines of best fit.
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tional file 7: Table S6 is that the ICERs are calculated
from varying perspectives. In addition, with the excep-
tion of the vaccine studies by Tediosi et al [40,41] and
an ITN study by Wiseman et al [42], which explicitly
include mass effects, all studies considered were
designed to evaluate the benefit of an intervention at
the individual level. ITNs and IRS are likely to have sub-
stantial additional benefits when applied on a large scale
since they can reduce the size of the vector population,
potentially reducing transmission, as well as providing
protection to individuals receiving the intervention.
Whilst these effects are captured in estimates of impact
of ITNs or IRS on morbidity outcomes from community
randomized trials, their true effect will vary by transmis-
sion setting and by coverage level and hence cannot
easily be extrapolated from one setting to another.
Discussion
A transparent evidence base on the costs and cost-effec-
tiveness of malaria control interventions is provided, to
inform resource allocation by international and domestic
financers of health programmes, and the selection of
optimal packages of interventions for malaria control
programme managers. The median financial cost per
ITN distributed was $7.03 (range $2.97-$19.20), $3.91
(range $1.11-$12.87) per household for IRS, $0.10 (range
$0.08-$0.18) for IPT in infants, $4.03 (range $1.25-
$11.80) for IPT in children, and $2.06 (range $0.47-
$3.36) for IPT in pregnant women. The median financial
cost of diagnosing a case of malaria was $4.32 (range
£0.34-$9.34). The median financial cost of treating an
episode of uncomplicated malaria was $5.84 (range
$2.36-$23.65) and the median financial cost of treating
an episode of severe malaria was $30.26 (range $15.64-
$137.87). The wide ranges in the estimates of unit costs
represent different durations of protection, and are a
consequence of the wide variation in the type of costing
study reviewed.
One of the key drawbacks of costing studies is that
they are often not undertaken alongside an evaluation of
the clinical and epidemiological effect of the interven-
tion under investigation. Thus it will cost the same to
distribute a bed net in an area of high transmission as
in an area of low transmission. Cost-effectiveness ana-
lyses incorporate information on both intervention costs
Figure 7 Cost-effectiveness of anti-malarial interventions against deaths averted, DALYs averted and cases of malaria averted.T h e
ICERs for ITN, IRS and IPT are against a baseline of no widespread preventive interventions. The ICERs for ACT are calculated against a baseline
of alternative treatment strategies, and hence care must be taken when comparing ICERs for preventive and treatment based interventions.
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Page 10 of 14and the impact on health. All of the major preventive
interventions and ACT treatment were consistently
cost-effective against a threshold of $150 per DALY
averted ($260 at 2009 prices) [34,35].
Care must be taken when comparing the cost-effec-
tiveness of prevention and treatment-based interven-
tions, as the denominator populations at risk may not
be directly comparable due to differences in age, loca-
tion, or exposure to malaria. Preventive interventions
are administered to individuals before future disease sta-
tus is known, (e.g. an ITN may be delivered to a person
who would not have become infected anyway) whereas
treatment with ACT is administered to an individual
conditional on them experiencing an episode of malaria
and coming into contact with a health facility where a
study is being undertaken. In studies of the cost-effec-
tiveness of preventive interventions, comparisons will
often be made between a population receiving the inter-
vention and a control population not receiving the inter-
vention. Such a study design is more difficult for
treatment-based interventions which must always com-
pare the treatment under investigation with an alterna-
tive treatment. These highlighted difficulties make direct
comparison of the cost-effectiveness of prevention and
treatment-based interventions difficult. In addition, the
cost of diagnosis and treatment programmes may
increase if active case detection is undertaken (searching
for cases) rather than passive. Although treatment and
prevention-based intervention will often be competing
for the same donor funds, they should be seen as com-
plementary and not in direct competition for resources.
The primary studies of costing data identified esti-
mated the costs of single interventions in the absence of
other anti-malaria interventions, with the exception of a
s t u d yb yP i c a r det al [43]. However estimates of the
costs and cost-effectiveness of combined interventions
were possible in model-based studies [21,22]. Given the
renewed enthusiasm for large-scale malaria control and
elimination efforts, control programmes based on multi-
ple interventions are becomingly increasingly common
[44-46]. Anti-malaria interventions will increasingly be
deployed as part of wider health system strengthening
packages leading to possible economies of scope: witness
the IPTi studies by Manzi et al [47] where the cost of a
course of intermittent preventive treatment was reduced
due to its administration alongside the already existing
(and therefore not an additional financial cost)
Expanded Programme on Immunization. Programme
donors such as The Global Fund and GAVI are com-
mitted to supporting linkages between malaria control
and strengthening of maternal, neonatal and child health
through harmonized funding platforms [48,49]. As such
it may be misleading to consider the costs of malaria
control in isolation.
The cost-effectiveness literature is also lacking in the
evaluation of combined malaria interventions. Apart
from the studies by Akhavan et al [25] and Mills [50] on
the evaluation of national or district level malaria control
programmes, only one study considers simultaneously
deployed interventions. Picard et al [43] compared the
cost-effectiveness of ITNs and ITNs with chemoprophy-
laxis and found that ITNs alone were more cost-effective
for averting malaria-associated deaths, but ITNs with
chemoprophylaxis were more cost-effective for averting
cases of malaria. Counter-intuitive results such as this are
not immediately obvious from separate studies of ITNs
and ITNs with chemoprophylaxis.
In the absence of detailed studies on the evaluation of
the costs and cost-effectiveness of combined interven-
tions, costing models can provide invaluable information
for individuals implementing malaria control pro-
grammes. Two such models stand out: (i) a decision tree
model by Goodman et al [21], building on an extensive
review of the cost-effectiveness literature [19], estimated
the cost-effectiveness of ITNs, IRS, chemoprophylaxis of
children, antenatal care and improvement of case man-
agement; and (ii) a costing and cost-effectiveness model
by Morel et al [22] based on data from the literature and
prices from the WHO-CHOICE database [51]. This
study estimated the cost-effectiveness of several combi-
nations of anti-malaria interventions (ACT, SP, CQ,
ITNs, IRS and IPT) in East and West African settings.
An important drawback of these models is that they
do not account for the dynamics of malaria transmis-
sion: model predictions of health impact assume a fixed
number of cases or deaths averted per unit of service/
output, so the additional benefit of mass effects and
their impact on the vector population (or, conversely,
possible saturation and overlap of interventions leading
to diminishing returns) at higher coverage levels are
ignored. One way to overcome these difficulties is by
incorporating cost-effectiveness evaluation into models
of the transmission dynamics of malaria. Tediosi et al
[41,52] and Smith et al [53] have developed a transmis-
sion model of the clinical epidemiology and natural his-
tory of P. falciparum for the evaluation of the cost-
effectiveness of an infection-blocking malaria vaccine,
and Ross et al have extended this model to intermittent
treatment [54]. This model captures the benefit of herd
immunity and allows cost-effectiveness to be estimated
across a range of transmission settings. These types of
models are ideally suited for evaluating the costs and
cost-effectiveness of combined malaria interventions.
In recent years there has been an encouraging increase
in the number of studies investigating the cost and cost-
effectiveness of key malaria control interventions (Figure
4). The costing methodology used in published studies has
significantly improved, with studies increasingly taking a
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recommendations of Creese and Parker [55] and Kolac-
zinski et al [18]. More detailed methodologies allow
greater comparability between studies and allow the
results to be generalised/extrapolated to other settings. For
example, if there is a known difference between sites in the
price of a net or insecticide but the costs accruing to the
supply chain can be assumed to be the same across set-
tings, then the cost of distributing an ITN can still be esti-
mated. One key area for improvement is the need for
more data collection in countries with a high malaria bur-
den and large populations as existing studies were clus-
tered around a few well-recognised sites in Tanzania,
Kenya and The Gambia (Figure 3).
All costs in this review have been presented in 2009 USD
to allow easy comparison between studies. However, focus-
ing on a single value to represent the cost of implementing
a malaria intervention can conceal a great deal of variation
in the methodology used to arrive at that figure. Final costs
can depend on the choice of costing components, the
method used for inflation, scale and scope of implementa-
tion, as well as local study factors. Sensitivity analyses go
some way towards capturing this variation in costs. In the
past decade, sensitivity analyses have become increasingly
sophisticated, developing from simple one-way analyses
where one costing component at a time is varied to prob-
abilistic sensitivity analyses where Monte Carlo methods
are used to vary multiple costing components simulta-
neously and produce a distribution of possible costs or
cost-effectiveness ratios. The variation in costs may also
depend on the scale of the study; larger studies may have
accurate estimates of total costs, but lack the detailed
record-keeping that is possible in smaller studies in more
controlled environments; whereas the costs in smaller stu-
dies can be affected by start-up and monitoring expenses.
There is still room to improve transparency and con-
sistency when reporting the assumptions, methodologies
and findings of economic evaluations to allow for
greater comparisons across interventions and thus help
decide the most appropriate strategies of treatment and
prevention. On a more positive note, however, increas-
ing cost and cost-effectiveness studies (both in terms of
their frequency and scale), improved modelling techni-
ques that enable us to extrapolate from small-scale stu-
dies to larger populations, and a recognition of the
importance of exploring variation and uncertainty asso-
ciated with costs as well as effects, has led to great
opportunities for economic evaluations to contribute to
the debate on which malaria interventions should be
deployed, and where, to achieve optimal heath gains.
Appendix 1
Three options exist for adjusting the cost of interven-
tions to their 2009 USD equivalent.
Method 1: Costs of interventions are first converted
from local currency to US dollars using the exchange
rate at the year of costing and then inflated to 2009
USD using USD inflation rates.
Method 2: Costs are first inflated to 2009 values in
the local currency and then converted to 2009 USD
using 2009 exchange rates.
Method 3: For studies where an ingredients approach
to costing has been used, a more detailed estimate of the
inflated cost can be obtained. The cost of an intervention
can be split into tradable costs (e.g. nets, insecticide,
drugs, treatment kits) and non-tradable costs (e.g. per-
sonnel, training, information, education and communica-
tion (IEC)). Tradable costs are first converted into US
dollars using exchange rates at the year of costing and
then inflated to 2009 USD. Non-tradable costs are first
inflated to 2009 values in the local currency and then
converted to 2009 USD using 2009 conversion rates.
There are strengths and weaknesses associated with all
the methods [27]. In this study, costs are inflated using
method 1 (converting then inflating) as the costs pub-
lished in many studies had already been converted to
US dollars and many studies did not use an ingredients
approach so it was not possible to identify the tradable
and non-tradable cost components.
The three methods for inflating the costs of interven-
tions are compared with the following examples:
Ngugi et al [56](Table 1): In a study in coastal and
western Kenya Ngugi et al [56] evaluated the cost to
employers of distributing ITNs to employees to be
$15.80 per net delivered in 2002 prices. 48% of the costs
were classified as tradable and 52% as non-tradable. The
exchange rates were 1 USD = 78 KSH in 2002 and 1
USD = 82 KSH in 2009.
Using method 1 (converting then inflating) the cost
per net distributed was estimated to be 2009 USD 19.20,
and using method 2 (inflating then converting) the cost
was estimated to be 2009 USD 18.27. Using method 3
resulted in the intermediate estimate of 2009 USD
18.72. As the Kenyan Shilling was stable against the dol-
lar there is not much difference between the three
methods.
Table 1 Methods for inflating the financial cost of ITNs as
reported by Ngugi et al [56] in 2002 USD to 2009 USD.
2002 2009
KSH USD KSH USD
Method 1 - 15.80 - 19.20
Method 2 1232.40 15.80 1497.86 18.27
Method 3 tradable 591.24 7.58 - 9.22
non-tradable 640.85 8.22 778.89 9.50
15.80 18.72
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Page 12 of 14Hanson et al [57](Table 2): In a Tanzanian study
Hanson et al [57] evaluated the cost of distributing
ITNs through a social marketing campaign. The cost
per net delivered was estimated to be $11.90 in 2000
prices. 49.6% of the costs were classified as tradable and
50.4% as non-tradable. The exchange rates were 1 USD
= 803 TSH in 2000 and 1 USD = 1355 TSH in 2009.
Using method 1 (converting then inflating) the cost
per net distributed was estimated to be 2009 USD 15.37,
and using method 2 (inflating then converting) the cost
was estimated to be 2009 USD 9.11. Using method 3
resulted in the intermediate estimate of 2009 USD
12.22. As the Tanzanian Shilling experienced high infla-
tion relative to the dollar there is significant variation
between the estimates of cost.
Additional material
Additional file 1: CostReview. Excel spreadsheet containing detailed
information costing studies reviewed.
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person protected by indoor residual spraying.
Additional file 4: Table S3. Table of financial and economic cost per
course/dose of intermittent preventive treatment.
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Additional file 6: Table S5. Table of financial and economic costs of
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